Treats locally advanced or metastatic ROS1- positive non-small cell lung cancer (NSCLC). Sold as Augtyro. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 1 application for Repotrectinib (sold as Augtyro), first approved Nov 15, 2023, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2024 | Change | Beneficiaries |
|---|---|---|---|---|
| Augtyro | Part D | $9.8M | New | 150 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA
